Lysine-specific modifications of p53: A matter of life and death?

Oncotarget

Volumn 4, Issue 10, 2013, Pages 1556-1571

  Marouco, Diana ^a   Garabadgiu, Alexander V ^b   Melino, Gerry ^a,b,c   Barlev, Nikolai A ^a,b,d  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ST PETERSBURG STATE INSTITUTE OF TECHNOLOGY TECHNICAL UNIVERSITY   (Russian Federation)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d INSTITUTE OF CYTOLOGY   (Russian Federation)

Author keywords

Acetylation; Lysine methylation; p53; Post translational modifications

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE PCAF; HISTONE LYSINE METHYLTRANSFERASE; LYSINE; METHYLTRANSFERASE; PROTEIN P53; PROTEIN P73; SET7 PROTEIN; SET8 PROTEIN; SET9 PROTEIN; SETD2 PROTEIN; SMYD2 PROTEIN; SMYD3 PROTEIN; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; BINDING AFFINITY; BINDING SITE; CHROMATIN; COMPLEX FORMATION; ENZYME ACTIVITY; ENZYME ASSAY; HISTONE MODIFICATION; HUMAN; METHYLATION; MOLECULAR DYNAMICS; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; UBIQUITINATION;

ANIMALS; BINDING SITES; HUMANS; LYSINE; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84886743570     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1436     Document Type: Article

References (127)

1. Levine AJ. The paths to death and differentiation. Cell death and differentiation. 2011; 18(9): 1391-2.
2. Soria C, Estermann FE, Espantman KC, O'Shea CC. Heterochromatin silencing of p53 target genes by a small viral protein. Nature. 2010; 466(7310): 1076-81.
3. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes & Development. 1998; 12(18): 2831-41.
4. Leonova KI, Brodsky L, Lipchick B, Pal M, Novototskaya L, Chenchik AA, Sen GC, Komarova EA, Gudkov A V. p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(1): E89-98.
5. Kibe R, Zhang S, Guo D, Marrero L, Tsien F, Rodriguez P, et al. IL-7Ra deficiency in p53null mice exacerbates thymocyte telomere erosion and lymphomagenesis. Cell death and differentiation. 2012; 19(7): 1139-51.
6. Lowe SW. Activation of p53 by oncogenes. Endocrine-related cancer. 1999; 6(1): 45-8.
7. Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell death & disease. 2011; 2: e164.
8. Gogna R, Madan E, Kuppusamy P, Pati U. Re-oxygenation causes hypoxic tumor regression through restoration of p53 wild-type conformation and post-translational modifications. Cell death & disease. 2012; 3: e286.
9. Boren J, Brindle KM. Apoptosis-induced mitochondrial dysfunction causes cytoplasmic lipid droplet formation. Cell death and differentiation. 2012; 19(9): 1561-70.
10. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon S-H, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 2012; 148(1-2): 244-58.
11. Maddocks ODK, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature. 2013; 493(7433): 542-6.
12. Speidel D. Transcription-independent p53 apoptosis: an alternative route to death. Trends in cell biology. 2010; 20(1): 14-24.
13. Sui X, Jin L, Huang X, Geng S, He C, Hu X. p53 signaling and autophagy in cancer: a revolutionary strategy could be developed for cancer treatment. Autophagy. 2011; 7(6): 565-71.
14. Bergeaud M, Mathieu L, Guillaume A, Moll UM, Mignotte B, Le Floch N, Vayssière J-L, Rincheval V. Mitochondrial p53 mediates a transcription-independent regulation of cell respiration and interacts with the mitochondrial F1F0-ATP synthase. Cell Cycle. 2013; 12(17): 2781-93.
15. Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell death & disease. 2011; 2: e148.
16. Davies L, Spiller D, White MRH, Grierson I, Paraoan L. PERP expression stabilizes active p53 via modulation of p53-MDM2 interaction in uveal melanoma cells. Cell death & disease. 2011; 2: e136.
17. Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes & Development. 1996; 10(19): 2438-51.
18. Inga A, Storici F, Darden TA, Resnick MA. Differential Transactivation by the p53 Transcription Factor Is Highly Dependent on p53 Level and Promoter Target Sequence. Molecular and cellular biology. 2002; 22(24): 8612-25.
19. Sims RJ, Reinberg D. Is there a code embedded in proteins that is based on post-translational modifications? Nature reviews Molecular cell biology. 2008; 9: 1-6.
20. Joerger AC, Fersht AR. Structural biology of the tumor suppressor p53. Annual review of biochemistry. 2008; 77: 557-82.
21. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell. 1997; 90(4): 595-606.
22. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell. 2008; 133(4): 612-26.
23. Liu L, Scolnick DM, Trievel RC, Bing H, Marmorstein R, Halazonetis TD, Berger SL, Liu LIN, Zhang HB. p53 Sites Acetylated In Vitro by PCAF and p300 Are Acetylated In Vivo in Response to DNA Damage. Molecular and cellular biology. 1999; 19(2): 1202-9.
24. Nagy Z, Tora L. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene. 2007; 26(37): 5341-57.
25. Di Stefano V, Soddu S, Sacchi A, D'Orazi G. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after nonapoptotic DNA damage. Oncogene. 2005; 24(35): 5431-42.
26. Chao C, Wu Z, Mazur SJ, Borges H, Rossi M, Lin T, Wang JYJ, Anderson CW, Appella E, Xu Y. Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Molecular and cellular biology. 2006; 26(18): 6859-69.
27. Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A, Quong A a, Zhang X, Beerman T, Pestell RG, Avantaggiati ML. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. The Journal of cell biology. 2006; 173(4): 533-44.
28. Cai B-H, Chen J-Y, Lu M-H, Chang L-T, Lin H-C, Chang Y-M, Chao C-F. Functional four-base A/T gap core sequence CATTAG of P53 response elements specifically bound tetrameric P53 differently than two-base A/T gap core sequence CATG bound both dimeric and tetrameric P53. Nucleic acids research. 2009; 37(6): 1984-90.
29. Love IM, Shi D, Grossman SR, Androphy J. The histone acetyltransferase PCAF regulates p21 transcription through stress-induced acetylation of histone H3. Cell Cycle. 2012; 11(13): 2458-66.
30. Sykes SM, Mellert HS, Holbert M a, Li K, Marmorstein R, Lane WS, McMahon SB. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Molecular cell. 2006; 24(6): 841-51.
31. Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis. Molecular cell. 2006; 24(6): 827-39.
32. Lill NL, Grossman SR, Ginsberg D, DeCaprio J, Livingston DM. Binding and modulation of p53 by p300/CBP coactivators. Nature. 1997; 387(6635): 823-7.
33. Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C. MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(10): 3895-900.
34. Barlev N a, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, Berger SL. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Molecular cell. 2001; 8(6): 1243-54.
35. Sachchidanand, Resnick-Silverman L, Yan S, Mutjaba S, Liu W-J, Zeng L, Manfredi JJ, Zhou M-M. Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chemistry & biology. 2006; 13(1): 81-90.
36. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Molecular cell. 2001; 8(1): 57-69.
37. Cesková P, Chichger H, Wallace M, Vojtesek B, Hupp TR. On the mechanism of sequence-specific DNA-dependent acetylation of p53: the acetylation motif is exposed upon DNA binding. Journal of molecular biology. 2006; 357(2): 442-56.
38. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R, Gu W. Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell. 2012; 149(6): 1269-83.
39. Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, Karnezis AN, Attardi LD. Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 2011; 145(4): 571-83.
40. Yamaguchi H, Woods NT, Piluso LG, Lee H, Chen J, Bhalla KN, Monteiro A, Liu X, Hung M, Wang H. p53 Acetylation Is Crucial for Its Transcription-independent Proapoptotic Functions. Journal of Biological Chemistry. 2009; 284(17): 11171-83.
41. Chen X, Wong JYC, Wong P, Radany EH. Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis. Molecular cancer research. 2011; 9(4): 448-61.
42. Schubert HL, Blumenthal RM, Cheng X. Many paths to methyltransfer: a chronicle of convergence. Trends in biochemical sciences. 2003; 28(6): 329-35.
43. Tschiersch B, Hofmann A, Krauss V, Dorn R, Korgel G, Reuter G. The protein encoded by the Drosophila position- combines domains of antagonistic regulators of homeotic gene complexes. EMBO Journal. 1994; 13(16): 3822-31.
44. Schapira M. Structural Chemistry of Human SET Domain Protein Methyltransferases. Current chemical genomics. 2011; 5(Suppl 1): 85-94.
45. Qian C, Zhou M-M. SET domain protein lysine methyltransferases: Structure, specificity and catalysis. Cellular and molecular life sciences. 2006; 63: 2755-63.
46. Trievel RC, Beach BM, Dirk LM a, Houtz RL, Hurley JH. Structure and catalytic mechanism of a SET domain protein methyltransferase. Cell. 2002; 111(1): 91-103.
47. Jenuwein T. Re-SET-ting heterochromatin by histone methyltransferases. Trends in cell biology. 2001; 11(6): 266-73.
48. Cheng, X Collins RZX. Structural and Sequence Motifs of Protein (Histone) Methylation Enzymes. Annu Rev Biophys Biomol Struct. 2005; (34): 267-94.
49. Scoumanne, A and Chen X. Protein methylation: a new regulator of the p53 tumor suppressor. Histol Histopathol. 2009; 23(9): 1143-9.
50. Shi Y, Lan F, Matson C, Mulligan P, Whetstine JR, Cole PA, Casero RA, Shi Y. Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1. Cell. 2004; 119: 941-53.
51. Tsukada Y, Fang J, Erdjument-Bromage H, Warren ME, Borchers CH, Tempst P, Zhang Y. Histone demethylation by a family of JmjC domain-containing proteins. Nature. 2006; 439(7078): 811-6.
52. Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M, Opravil S, Mechtler K, Ponting CP, Allis CD, Jenuwein T. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature. 2000; 406(6796): 593-9.
53. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes & development. 2002; 16(22): 2893-905.
54. Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y. Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002; 298: 1039-43.
55. Schotta G, Lachner M, Sarma K, Ebert A, Sengupta R, Reuter G, Reinberg D, Jenuwein T. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes & development. 2004; 18(11): 1251-62.
56. Huang J, Berger SL. The emerging field of dynamic lysine methylation of non-histone proteins. Current opinion in genetics & development. 2008; (18): 152-8.
57. Morgunkova A, Barlev NA. Lysine Methylation goes global. Cell Cycle. 2006; 12(5): 1308-12.
58. Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, Mckinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D. Regulation of p53 activity through lysine methylation. Nature. 2004; 432(18): 353-60.
59. Ivanov GS, Ivanova T, Kurash J, Ivanov A, Chuikov S, Gizatullin F, Herrera-Medina EM, Rauscher F, Reinberg D, Barlev N. a. Methylation-acetylation interplay activates p53 in response to DNA damage. Molecular and cellular biology. 2007; 27(19): 6756-69.
60. Lehnertz B, Rogalski JC, Schulze FM, Yi L, Lin S, Kast J, Rossi FM V. p53-dependent transcription and tumor suppression are not affected in Set7/9-deficient mice. Molecular cell. 2011; 43(4): 673-80.
61. Campaner S, Spreafico F, Burgold T, Doni M, Rosato U, Amati B, Testa G. The methyltransferase Set7/9 (Setd7) is dispensable for the p53-mediated DNA damage response in vivo. Molecular Cell. Elsevier Inc. 2011; 43: 681-8.
62. Kurash JK, Lei H, Shen Q, Marston WL, Granda BW, Fan H, Wall D, Li E. Methylation of p53 by Set7/9Mediates p53 Acetylation and Activity In Vivo. Molecular cell. 2008; (29): 392-400.
63. Iwakuma T, Lozano G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene. 2007; 26(15): 2177-84.
64. Kenzelmann Broz D, Attardi LD. In vivo analysis of p53 tumor suppressor function using genetically engineered mouse models. Carcinogenesis. 2010; 31(8): 1311-8.
65. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature reviews Cancer. 2006; 6(12): 909-23.
66. Huang J, Perez-burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, Kubicek S, Opravil S, Jenuwein T, Berger SL. Repression of p53 activity by Smyd2-mediated methylation. Nature. 2006; 444(30): 629-32.
67. Brown M a, Sims RJ, Gottlieb PD, Tucker PW. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex. Molecular cancer. 2006; 5: 26.
68. Xu S, Zhong C, Zhang T, Ding J. Structure of human lysine methyltransferase Smyd2 reveals insights into the substrate divergence in Smyd proteins. Journal of molecular cell biology. 2011; 3(5): 293-300.
69. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey J a, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. p53 is regulated by the lysine demethylase LSD1. Nature. 2007; 449(7158): 105-8.
70. Scoumanne A, Chen X. The lysine-specific demethylase 1 is required for cell proliferation in both p53-dependent and -independent manners. The Journal of biological chemistry. 2007; 282(21): 15471-5.
71. Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, Dutta S, Appella E, Gozani O. Modulation of p53 function by SET8-mediated methylation at lysine 382. Molecular cell. 2007; 27(4): 636-46.
72. West LE, Roy S, Lachmi-Weiner K, Hayashi R, Shi X, Appella E, Kutateladze TG, Gozani O. The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. The Journal of biological chemistry. 2010; 285(48): 37725-32.
73. Huang J, Dorsey J, Chuikov S, Zhang X, Jenuwein T, Reinberg D, Berger SL. G9a and Glp Methylate Lysine 373 in the Tumor Supressor p53. The Journal of biological chemistry. 2010; 285(13): 9636-41.
74. Xie P, Tian C, An L, Nie J, Lu K, Xing G, Zhang L, He F. Histone methyltransferase protein SETD2 interacts with p53 and selectively regulates its downstream genes. Cellular signalling. 2008; 20(9): 1671-8.
75. Abu-Farha M, Lanouette S, Elisma F, Tremblay V, Butson J, Figeys D, Couture J-F. Proteomic analyses of the SMYD family interactomes identify HSP90 as a novel target for SMYD2. Journal of molecular cell biology. 2011; 3(5): 301-8.
76. Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva FP, Li M, Yagyu R, Nakamura Y. SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nature cell biology. 2004; 6(8): 731-40.
77. Foreman KW, Brown M, Park F, Emtage S, Harriss J, Das C, Zhu L, Crew A, Arnold L, Shaaban S, Tucker P. Structural and functional profiling of the human histone methyltransferase SMYD3. PloS one. 2011; 6(7): e22290.
78. Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos A-F, et al. Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation. Epigenetics: official journal of the DNA Methylation Society. 2012; 7(4): 340-3.
79. Kunizaki M, Hamamoto R, Silva FP, Yamaguchi K, Nagayasu T, Shibuya M, Nakamura Y, Furukawa Y. The lysine 831 of vascular endothelial growth factor receptor 1 is a novel target of methylation by SMYD3. Cancer research. 2007; 67(22): 10759-65.
80. Mittenberg A, Moiseeva T, Barlev N. Role of proteasomes in transcription and their regulation by covalent modifications. Front Biosci. 2008; 1(13): 7184-92.
81. Giaccia a. J, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes & Development. 1998; 12(19): 2973-83.
82. Le Cam L, Linares LK, Paul C, Julien E, Lacroix M, Hatchi E, Triboulet R, Bossis G, Shmueli A, Rodriguez MS, Coux O, Sardet C. E4F1 is an atypical ubiquitin ligase that modulates p53 effector functions independently of degradation. Cell. 2006; 127(4): 775-88.
83. Wu S-Y, Chiang C-M. Crosstalk between sumoylation and acetylation regulates p53-dependent chromatin transcription and DNA binding. The EMBO journal. 2009; 28(9): 1246-59.
84. Liu X, Wang D, Zhao Y, Tu B, Zheng Z, Wang L, Wang H, Gu W, Roeder RG, Zhu W-G. Methyltransferase Set7/9 regulates p53 activity by interacting with Sirtuin 1 (SIRT1). Proceedings of the National Academy of Sciences of the United States of America. 2011; 108(5): 1925-30.
85. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Do V, Andrews NC, Caput D, Mckeon F. p63, a p53 Homolog at 3q27-29, Encodes Multiple Products with Transactivating , Death-Inducing , and Dominant-Negative Activities. Molecular Cell. 1998; 2: 305-16.
86. Yang a, McKeon F. P63 and P73: P53 mimics, menaces and more. Nature reviews Molecular cell biology. 2000; 1(3): 199-207.
87. Melino G, De Laurenzi V, Vousden KH. p73: Friend or foe in tumorigenesis. Nature reviews Cancer. 2002; 2(8): 605-15.
88. Murray-Zmijewski F, Lane DP, Bourdon J-C. P53/P63/P73 Isoforms: an Orchestra of Isoforms To Harmonise Cell Differentiation and Response To Stress. Cell death and differentiation. 2006; 13(6): 962-72.
89. Zeng X, Li X, Miller a, Yuan Z, Yuan W, Kwok RP, Goodman R, Lu H. The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Molecular and cellular biology. 2000; 20(4): 1299-310.
90. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole P a, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C, Levrero M. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Molecular cell. 2002; 9(1): 175-86.
91. Zeng X, Lee H, Zhang Q, Lu H. P300 Does Not Require Its Acetylase Activity To Stimulate P73 Function. The Journal of biological chemistry. 2001; 276(1): 48-52.
92. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, et al. The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Molecular cell. 2005; 18(4): 447-59.
93. Levy D, Adamovich Y, Reuven N, Shaul Y. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73. Cell death and differentiation. 2007; 14(4): 743-51.
94. Dai JINM, Wang ZHIYAN, Sun DAOC, Lin RUX, Wang SQI. SIRT1 Interacts With p73 and Suppresses p73-Dependent Transcriptional Activity. Journal of Cellular Physiology. 2007; (210): 161-6.
95. Malatesta M, Peschiaroli a, Memmi EM, Zhang J, Antonov a, Green DR, Barlev N a, Garabadgiu a V, Zhou P, Melino G, Bernassola F. The Cul4A-DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity. Oncogene. Nature Publishing Group. 2012; (March): 1-6.
96. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G, Pandolfi PP. Ubiquitin-dependent degradation of p73 is inhibited by PML. The Journal of experimental medicine. 2004; 199(11): 1545-57.
97. MacPartlin M, Zeng S, Lee H, Stauffer D, Jin Y, Thayer M, Lu H. P300 Regulates P63 Transcriptional Activity. The Journal of biological chemistry. 2005; 280(34): 30604-10.
98. Ramsey MR, He L, Forster N, Ory B, Ellisen LW. Physical association of HDAC1 and HDAC2 with p63 mediates transcriptional repression and tumor maintenance in squamous cell carcinoma. Cancer research. 2011; 71(13): 4373-9.
99. Chae Y-S, Kim H, Kim D, Lee H, Lee H. Cell density-dependent acetylation of δNp63a is associated with p53-dependent cell cycle arrest. FEBS letters. Federation of European Biochemical Societies. 2012; 586(8): 1128-34.
100. Watson IR, Irwin MS. Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia. 2006; 8(8): 655-66.
101. Fomenkov A, Zangen R, Huang Y, Osada M, Guo Z, Fomenkov T, Trink B, Sidransky D, Ratovitski EA. RACK1 and Stratifin Target δ Np63 a for a Proteasome Degradation in Head and Neck Squamous Cell Carcinoma Cells upon DNA Damage Report. Cell Cycle. 2004; 3(10): e27-e37.
102. Bakkers J, Camacho-carvajal M, Nowak M, Hammerschmidt M. Destabilization of DeltaNp63alpha by Nedd4-mediated ubiquitination and Ubc9-mediated sumoylation, and its implications on dorsoventral patterning of the zebrafish embryo. Cell Cycle. 2005; 4(6): 790-800.
103. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA, Croce CM, Melino G. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proceedings of the National Academy of Sciences of the United States of America. 2006; 103(34): 12753-8.
104. Jenuwein T, Allis CD. Translating the histone code. Science. 2001; 293: 1074-80.
105. Sampath SC, Marazzi I, Yap KL, Sampath SC, Krutchinsky AN, Mecklenbräuker I, Viale A, Rudensky E, Zhou M-M, Chait BT, Tarakhovsky A. Methylation of a histone mimic within the histone methyltransferase G9a regulates protein complex assembly. Molecular cell. 2007; 27(4): 596-608.
106. West LE, Gozani O. Regulation of p53 function by lysine methylation. Epigenomics. 2011; 3(3): 361-9.
107. Zentner GE, Henikoff S. Regulation of nucleosome dynamics by histone modifications. Nature structural & molecular biology. Nature Publishing Group. 2013; 20(3): 259-66.
108. Kouzarides T. Histone methylation in transcriptional control. Current opinion in genetics & development. 2002; 12(2): 198-209.
109. Nishioka K, Chuikov S, Sarma K, Erdjument-bromage H, Allis CD, Tempst P, Reinberg D. Set9 , a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes & Development. 2002; 16: 479-89.
110. Wang H, Cao R, Xia L, Erdjument-bromage H, Borchers C, Tempst P, Zhang Y, Hill C, Carolina N. Purification and Functional Characterization of a Histone H3-Lysine 4-Specific Methyltransferase. Molecular cell. 2001; 8: 1207-17.
111. Komatsu S, Imoto I, Tsuda H, Kozaki K, Muramatsu T, Shimada Y, Aiko S, Yoshizumi Y, Ichikawa D, Otsuji E, Inazawa J. Overexpression of SMYD2 relates to tumor cell proliferation and malignant outcome of esophageal squamous cell carcinoma. Carcinogenesis. 2009; 30(7): 1139-46.
112. Fang J, Feng Q, Ketel CS, Wang H, Cao R, Xia L, Erdjument-bromage H, Tempst P, Simon JA, Zhang Y, Hill C, Carolina N. Purification and Functional Characterization of SET8 , a Nucleosomal Histone H4- Lysine 20-Specific Methyltransferase University of North Carolina at Chapel Hill. 2002; 12(02): 1086-99.
113. Vakoc CR, Sachdeva MM, Wang H, Blobel G a. Profile of histone lysine methylation across transcribed mammalian chromatin. Molecular and cellular biology. 2006; 26(24): 9185-95.
114. Talasz H, Lindner HH, Sarg B, Helliger W. Histone H4-lysine 20 monomethylation is increased in promoter and coding regions of active genes and correlates with hyperacetylation. The Journal of biological chemistry. 2005; 280(46): 38814-22.
115. Nishioka K, Rice JC, Sarma K, Erdjument-bromage H, Werner J, Wang Y, et al. PR-Set7 Is a Nucleosome-Specific Methyltransferase that Modifies Lysine 20 of Histone H4 and Is Associated with Silent Chromatin. Molecular Cell. 2002; 9: 1201-13.
116. Congdon LM, Houston SI, Veerappan CS, Spektor TM, Rice JC. PR-Set7-mediated monomethylation of histone H4 lysine 20 at specific genomic regions induces transcriptional repression. Journal of cellular biochemistry. 2010; 110(3): 609-19.
117. Tachibana M, Sugimoto K, Fukushima T, Shinkai Y. Set domain-containing protein, G9a, is a novel lysine-preferring mammalian histone methyltransferase with hyperactivity and specific selectivity to lysines 9 and 27 of histone H3. The Journal of biological chemistry. 2001; 276(27): 25309-17.
118. Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature. 2001; 410(6824): 116-20.
119. Bannister a J, Zegerman P, Partridge JF, Miska E a, Thomas JO, Allshire RC, Kouzarides T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature. 2001; 410(6824): 120-4.
120. Fischle W, Wang Y, Jacobs SA, Kim Y, Allis CD. Molecular basis for the discrimination of repressive methyl-lysine marks in histone H3 by Polycomb and HP1 chromodomains. Genes & Development. 2003; 17: 1870-81.
121. Tachibana M, Sugimoto K, Nozaki M, Ueda J, Ohta T, Ohki M, Fukuda M, Takeda N, Niida H, Kato H, Shinkai Y. G9a histone methyltransferase plays a dominant role in euchromatic histone H3 lysine 9 methylation and is essential for early embryogenesis. Genes & Development. 2002; 16: 1779-91.
122. Taverna SD, Ilin S, Rogers RS, Tanny JC, Lavender H, Li H, et al. Yng1 PHD finger binding to H3 trimethylated at K4 promotes NuA3 HAT activity at K14 of H3 and transcription at a subset of targeted ORFs. Molecular cell. 2006; 24(5): 785-96.
123. Lee J, Kim D-H, Lee S, Yang Q-H, Lee DK, Lee S-K, Roeder RG, Lee JW. A tumor suppressive coactivator complex of p53 containing ASC-2 and histone H3-lysine-4 methyltransferase MLL3 or its paralogue MLL4. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(21): 8513-8.
124. Mungamuri SK, Benson EK, Wang S, Gu W, Lee SW, Aaronson S a. P53-Mediated Heterochromatin Reorganization Regulates Its Cell Fate Decisions. Nature structural & molecular biology. Nature Publishing Group. 2012; 19(5): 478-84, S1.
125. Moellering RE, Cravatt BF. Functional lysine modification by an intrinsically reactive primary glycolytic metabolite. Science. 2013; 341(6145): 549-53.
126. Wanka C, Brucker DP, Bähr O, Ronellenfitsch M, Weller M, Steinbach JP, Rieger J. Synthesis of cytochrome C oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. Oncogene. 2012; 31(33): 3764-76.
127. Dion MF, Altschuler SJ, Wu LF, Rando OJ. Genomic characterization reveals a simple histone H4 acetylation code. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(15): 5501-6.